A Clinical Role of PET in Atherosclerosis and Vulnerable Plaques?

Area of Science:

• Cardiovascular Medicine
• Medical Imaging
• Nuclear Medicine

Background:

• Atherosclerosis is a progressive disease characterized by plaque instability, rupture, and erosion, leading to atherothrombotic events.
• Plaque composition, particularly inflammation, dictates its progression from asymptomatic to symptomatic stages.
• Inflammation within atherosclerotic plaques is a key driver of disease progression and instability.

Purpose of the Study:

• To review the role of Positron Emission Tomography (PET) imaging in exploring metabolic activities within atherosclerotic plaques.
• To highlight evidence from clinical studies using Fluorodeoxyglucose (FDG)-PET for assessing plaque inflammation.
• To discuss future perspectives of novel radiopharmaceuticals for vulnerable plaque imaging.

Main Methods:

• Review of clinical studies utilizing FDG-PET for atherosclerotic plaque imaging.
• Exploration of molecular imaging techniques, focusing on PET's sensitivity for detecting radiopharmaceuticals in vascular tissues.
• Assessment of plaque features using noninvasive imaging modalities like CT angiography, MRI, and PET.

Main Results:

• FDG-PET imaging has emerged as a significant tool for noninvasively evaluating inflammatory activity in atherosclerotic plaques.
• PET imaging provides insights into the dynamic metabolic changes occurring in the vascular wall over time.
• Evidence from clinical studies supports FDG-PET's utility in characterizing plaque biology.

Conclusions:

• PET imaging, especially FDG-PET, is crucial for understanding the inflammatory processes in atherosclerosis.
• This modality offers a noninvasive window into the metabolic state of atherosclerotic plaques.
• Future developments in radiopharmaceuticals hold promise for enhanced vulnerable plaque detection and characterization.